C
Claus Hagen
Researcher at Odense University Hospital
Publications - 139
Citations - 7121
Claus Hagen is an academic researcher from Odense University Hospital. The author has contributed to research in topics: Prolactin & Luteinizing hormone. The author has an hindex of 45, co-authored 139 publications receiving 6888 citations. Previous affiliations of Claus Hagen include Hvidovre Hospital & Herlev Hospital.
Papers
More filters
Journal ArticleDOI
Incidence and late prognosis of cushing's syndrome: a population-based study.
Jörgen Lindholm,Svend Juul,Jens Otto Lunde Jørgensen,Jens Astrup,P. Bjerre,Ulla Feldt-Rasmussen,Claus Hagen,J.O.L. Jørgensen,M. Kosteljanetz,Lars Østergaard Kristensen,Peter Laurberg,K. Schmidt,Jørgen Weeke +12 more
TL;DR: Cushing's syndrome is rare and is associated with increased mortality, in patients with no concurrent malignancy also; the excess mortality was mainly observed during the first year of disease; and the impaired quality of health in long-term survivors of Cushing's disease is not fully explained.
Journal ArticleDOI
Prevention of early postmenopausal bone loss: controlled 2-year study in 315 normal females.
Claus Christiansen,M. S. Christensen,Peter McNair,Claus Hagen,Knud-Erik Stocklund,Ib Transbøl +5 more
TL;DR: This study randomized 315 healthy volunteers in their early natural menopause to seven treatment and three placebo groups, with the aim of preventing postmenopausal bone loss.
Journal ArticleDOI
Kinetics of human connecting peptide in normal and diabetic subjects.
O K Faber,Claus Hagen,Chr. Binder,J Markussen,V K Naithani,Petra M. Blix,Hideshi Kuzuya,David L. Horwitz,Arthur H. Rubenstein,N Rossing +9 more
TL;DR: The difference in the half-life of C-peptide in plasma between diabetics and normals suggests an altered kinetics of the disappearance of the peptide, while the overall metabolism, as expressed by the MCR, is similar.
Journal ArticleDOI
Fractures in patients with anorexia nervosa, bulimia nervosa, and other eating disorders—A nationwide register study
Peter Vestergaard,Charlotte Emborg,René Klinkby Støving,Claus Hagen,Leif Mosekilde,Kim Brixen +5 more
TL;DR: Fracture risk was increased in AN after diagnosis compared to controls, and the increased fracture risk persisted more than 10 years after diagnosis, indicating permanent skeletal damage.
Journal ArticleDOI
Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist.
Jens Otto Lunde Jørgensen,Ulla Feldt-Rasmussen,Jan Frystyk,Jian-Wen Chen,Lars Østergård Kristensen,Claus Hagen,Hans Ørskov +6 more
TL;DR: Dual blockade of the GH axis with pegvisomant and a SMS analog is feasible in acromegaly.